|
|
||
|
|
May 30, 2016 Issue |
||
|
The Most Powerful Name In Corporate News and Information |
|||
|
Advanced Cannabinoid-based Cancer Research, Treatments and Therapies Focused on the Right Route of Delivery |
|||
|
CEO & Co-Founder
(OTCB-CNBX)
Interview conducted by: Lynn Fosse, Senior Editor, CEOCFO Magazine, Published – May 30, 2016
CEOCFO: Mr. Borochov, would you tell us the focus at Cannabics today? Mr. Borochov: We are pioneers in the recruitment of high throughput screening (HTS) technology to evaluate anti-cancer properties of cannabinoid compounds through the assessment of their biological activity on cancer cell lines and patients’ tumor cells. Cross linked with a growing database, patients may receive a personalized cannabis therapy with no side effects or toxicity related to chemotherapy.
CEOCFO: When you started the research, did you know it would work and it was just a matter of finding the right ratios? Mr. Borochov: The research began in 2015, utilizing high-throughput technology, we screen for antitumor effects, mainly apoptosis and proliferation, on cell lines and tumor cells treated with arrays of plant extracts. This lab test of extracts found to have the most prominent antitumor properties will be given to doctor/patients. We offer doctors and their patients our proprietary diagnostic system, which allows personalized treatments.
CEOCFO: Do we know why it works? Mr. Borochov: Nobody knows yet.
CEOCFO: Is the medical community paying attention? Mr. Borochov: We are a small company and do not have the financial resources to spread the message. We are not a big pharmaceutical company that can afford to make a big deal out of everything they do. But as a public company we get pretty nice free coverage.
CEOCFO: What is the strategy for the upcoming year, to change that? Mr. Borochov: We hope to raise $ 2 million in the coming months, through a private placement, this amount would be enough for us to move to the next level. We want to sell our products and technologies also in Europe, Australia, Canada and South America.
CEOCFO: What has been the reaction in Israel and what are the regulations around cannabis in Israel? Mr. Borochov: Israel has the world's most advanced medical cannabis regulation, only in Israel you can carry out clinical trials that examine the effects of cannabis, but there are only fifteen thousand patients in Israel with license for medical cannabis. It is not a big market for us.
CEOCFO: What has happened so far in Colorado? Mr. Borochov: Colorado is very interesting because they have recreational market and medical market. The recreational market controls 80% of the market and the medical market is 20%. The business is in the recreational market. There are nine hundred dispensaries there.
In 2014, Our Company and Wana Edible, a Colorado corporation based in Boulder, Colorado executed a license agreement for the exclusive production and distribution of Cannabics SR technology in the USA under the label Wanacaps XR.
CEOCFO: What are some of the different types of capsules you have? Mr. Borochov: Three versions of our capsules are currently available in Colorado market: High THC Capsules 10 mg of THC, 1 mg of CBD. THC/CBD Balanced Capsules - 10 mg of THC and 10 mg of CBD. High CBD Capsules 10 mg of CBD, 1 mg of THC.
CEOCFO: Why pay attention to Cannabics Pharmaceutical Inc. today? Mr. Borochov: Our clinical study is currently underway in the Oncology Department of the Rambam Medical Center in Israel in order to examine the effectiveness of our Cannabics SR capsule in reducing nausea and improving the appetite of oncology patients as well as general improvement in quality of life and reduction of depression. We expect the first results to be available in October 2016. You can find this study under “Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients” or from the NIH Clinical Trials website: |
“Cross linked with a growing database, patients may receive a personalized cannabis therapy with no side effects or toxicity related to chemotherapy.” - Itamar Borochov
(OTCB-CNBX)
Itamar Borochov +972-549-487653
|
||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
Itamar
Borochov